Interstitial pneumonitis as an adverse reaction to mTOR inhibitors
Neumonitis intersticial como reacción adversa a inhibidores de mTOR
Read
12560
Timeswas read the article
4104
Total PDF
8456
Total HTML
Share statistics
array:21 [ "pii" => "X2013251413003279" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2013.Jan.11439" "estado" => "S300" "fechaPublicacion" => "2013-05-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2013;33:297-300" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 6274 "formatos" => array:3 [ "EPUB" => 307 "HTML" => 5142 "PDF" => 825 ] ] "Traduccion" => array:1 [ "es" => array:17 [ "pii" => "X0211699513003271" "issn" => "02116995" "doi" => "10.3265/Nefrologia.pre2013.Jan.11439" "estado" => "S300" "fechaPublicacion" => "2013-05-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2013;33:297-300" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 13149 "formatos" => array:3 [ "EPUB" => 298 "HTML" => 12087 "PDF" => 764 ] ] "es" => array:12 [ "idiomaDefecto" => true "titulo" => "Neumonitis intersticial como reacción adversa a inhibidores de mTOR" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "297" "paginaFinal" => "300" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Interstitial pneumonitis as an adverse reaction to mTOR inhibitors" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig1" "etiqueta" => "Tab. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11439_19904_28254_es_11439_t1.jpg" "Alto" => 449 "Ancho" => 900 "Tamanyo" => 194782 ] ] "descripcion" => array:1 [ "es" => "Principales estudios sobre neumonitis en pacientes en tratamiento con inhibidores de mTOR" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Gloria Molas Ferrer, Gloria Molas-Ferrer, Dolors Soy Muner, Dolors Soy-Muner, Helena Anglada Martínez, Helena Anglada-Martínez, Gisela Riu Viladoms, Gisela Riu-Viladoms, Anna Estefanell Tejero, Anna Estefanell-Tejero, Josep Ribas Sala, Josep Ribas-Sala" "autores" => array:12 [ 0 => array:2 [ "nombre" => "Gloria" "apellidos" => "Molas Ferrer" ] 1 => array:2 [ "nombre" => "Gloria" "apellidos" => "Molas-Ferrer" ] 2 => array:2 [ "nombre" => "Dolors" "apellidos" => "Soy Muner" ] 3 => array:2 [ "nombre" => "Dolors" "apellidos" => "Soy-Muner" ] 4 => array:2 [ "nombre" => "Helena" "apellidos" => "Anglada Martínez" ] 5 => array:2 [ "nombre" => "Helena" "apellidos" => "Anglada-Martínez" ] 6 => array:2 [ "nombre" => "Gisela" "apellidos" => "Riu Viladoms" ] 7 => array:2 [ "nombre" => "Gisela" "apellidos" => "Riu-Viladoms" ] 8 => array:2 [ "nombre" => "Anna" "apellidos" => "Estefanell Tejero" ] 9 => array:2 [ "nombre" => "Anna" "apellidos" => "Estefanell-Tejero" ] 10 => array:2 [ "nombre" => "Josep" "apellidos" => "Ribas Sala" ] 11 => array:2 [ "nombre" => "Josep" "apellidos" => "Ribas-Sala" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "X2013251413003279" "doi" => "10.3265/Nefrologia.pre2013.Jan.11439" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251413003279?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699513003271?idApp=UINPBA000064" "url" => "/02116995/0000003300000003/v0_201502091323/X0211699513003271/v0_201502091323/es/main.assets" ] ] "itemSiguiente" => array:17 [ "pii" => "X2013251413003260" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2013.Feb.11638" "estado" => "S300" "fechaPublicacion" => "2013-05-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2013;33:301-7" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 5786 "formatos" => array:3 [ "EPUB" => 314 "HTML" => 4708 "PDF" => 764 ] ] "en" => array:12 [ "idiomaDefecto" => true "titulo" => "New models of integrated health care management in nephrology" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "301" "paginaFinal" => "307" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Nuevos modelos de gestión de asistencia integral en nefrología" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig1" "etiqueta" => "Tab. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11638_16025_46351_en_t1116383.jpg" "Alto" => 931 "Ancho" => 2143 "Tamanyo" => 334597 ] ] "descripcion" => array:1 [ "en" => "Differences between the different models of reimbursement for medical services" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Rosa Ramos, Manolo Molina" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Rosa" "apellidos" => "Ramos" ] 1 => array:2 [ "nombre" => "Manolo" "apellidos" => "Molina" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "X0211699513003263" "doi" => "10.3265/Nefrologia.pre2013.Feb.11638" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699513003263?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251413003260?idApp=UINPBA000064" "url" => "/20132514/0000003300000003/v0_201502091549/X2013251413003260/v0_201502091549/en/main.assets" ] "itemAnterior" => array:17 [ "pii" => "X2013251413003287" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2012.Oct.11592" "estado" => "S300" "fechaPublicacion" => "2013-05-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2013;33:289-96" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 10524 "formatos" => array:3 [ "EPUB" => 294 "HTML" => 9167 "PDF" => 1063 ] ] "en" => array:12 [ "idiomaDefecto" => true "titulo" => "Distal renal tubular acidosis: a hereditary disease with an inadequate urinary H+ excretion" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "289" "paginaFinal" => "296" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "La acidosis tubular renal distal: una enfermedad hereditaria en la que no se pueden eliminar los hidrogeniones" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig1" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11592_16025_44702_en_f211592i.jpg" "Alto" => 532 "Ancho" => 1018 "Tamanyo" => 147905 ] ] "descripcion" => array:1 [ "en" => "Topology of the erythrocyte AE1 Cl-/HCO3- exchanger" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Laura Escobar, Natalia Mejía, Helena Gil, Fernando Santos" "autores" => array:7 [ 0 => array:2 [ "nombre" => "Laura" "apellidos" => "Escobar" ] 1 => array:2 [ "nombre" => "Laura" "apellidos" => "Escobar" ] 2 => array:2 [ "nombre" => "Natalia" "apellidos" => "Mejía" ] 3 => array:2 [ "nombre" => "Helena" "apellidos" => "Gil" ] 4 => array:2 [ "nombre" => "Helena" "apellidos" => "Gil" ] 5 => array:2 [ "nombre" => "Fernando" "apellidos" => "Santos" ] 6 => array:2 [ "nombre" => "Fernando" "apellidos" => "Santos" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "X021169951300328X" "doi" => "10.3265/Nefrologia.pre2012.Oct.11592" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X021169951300328X?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251413003287?idApp=UINPBA000064" "url" => "/20132514/0000003300000003/v0_201502091549/X2013251413003287/v0_201502091549/en/main.assets" ] "en" => array:15 [ "idiomaDefecto" => true "titulo" => "Interstitial pneumonitis as an adverse reaction to mTOR inhibitors" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "297" "paginaFinal" => "300" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "Gloria Molas Ferrer, Gloria Molas-Ferrer, Dolors Soy Muner, Dolors Soy-Muner, Helena Anglada Martínez, Helena Anglada-Martínez, Gisela Riu Viladoms, Gisela Riu-Viladoms, Anna Estefanell Tejero, Anna Estefanell-Tejero, Josep Ribas Sala, Josep Ribas-Sala" "autores" => array:12 [ 0 => array:4 [ "nombre" => "Gloria" "apellidos" => "Molas Ferrer" "email" => array:1 [ 0 => "gmolas@clinic.ub.es" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 1 => array:4 [ "nombre" => "Gloria" "apellidos" => "Molas-Ferrer" "email" => array:1 [ 0 => "gmolas@clinic.ub.es" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] 2 => array:3 [ "nombre" => "Dolors" "apellidos" => "Soy Muner" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 3 => array:3 [ "nombre" => "Dolors" "apellidos" => "Soy-Muner" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] 4 => array:3 [ "nombre" => "Helena" "apellidos" => "Anglada Martínez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 5 => array:3 [ "nombre" => "Helena" "apellidos" => "Anglada-Martínez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] 6 => array:3 [ "nombre" => "Gisela" "apellidos" => "Riu Viladoms" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 7 => array:3 [ "nombre" => "Gisela" "apellidos" => "Riu-Viladoms" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] 8 => array:3 [ "nombre" => "Anna" "apellidos" => "Estefanell Tejero" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 9 => array:3 [ "nombre" => "Anna" "apellidos" => "Estefanell-Tejero" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] 10 => array:3 [ "nombre" => "Josep" "apellidos" => "Ribas Sala" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 11 => array:3 [ "nombre" => "Josep" "apellidos" => "Ribas-Sala" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Servicio de Farmacia Hospitalaria, Hospital Clínic de Barcelona, Barcelona, Barcelona, Spain, " "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] 1 => array:3 [ "entidad" => "Servicio de Farmacia Hospitalaria, Hospital Clínic de Barcelona, " "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Neumonitis intersticial como reacción adversa a inhibidores de mTOR" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig1" "etiqueta" => "Tab. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11439_16025_46549_en_t111439.jpg" "Alto" => 1065 "Ancho" => 2167 "Tamanyo" => 348743 ] ] "descripcion" => array:1 [ "en" => "Main studies on pneumonitis in patients treated with mTOR inhibitors" ] ] ] "textoCompleto" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">INTRODUCTION</span></p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">mTOR (<span class="elsevierStyleItalic">mammalian target of rapamycin</span>) inhibitors, sirolimus (rapamycin) and everolimus, act by inhibiting T and B lymphocyte proliferation. They were proposed as a safer alternative to immunosuppressant treatment of solid organ transplantations, compared with calcineurin inhibitors already widely used, such as tacrolimus and cyclosporine. However, in clinical practice, it has been demonstrated that mTOR inhibitors are not exempt from toxicity.<span class="elsevierStyleSup">1</span> At the time of their introduction to the market, the absence of nephrotoxicity was highlighted as its main advantage over calcineurin inhibitors but subsequent studies on patients with a kidney transplant called into question this assertion.<span class="elsevierStyleSup">2,3</span></p><p class="elsevierStylePara">The pharmacokinetics of sirolimus and everolimus are very similar in terms of metabolism and excretion. Both are metabolised by CYP3A4 to inactive metabolites, which are fundamentally eliminated through faeces, with excretion through the kidney being minimal. The pharmacokinetic parameters, which are altered in the event of liver failure, are not affected by renal failure. Both drugs are also substrates of P-glycoprotein, which is involved in the clearance processes. The elimination half-life is about 30 hours for everolimus and around double for sirolimus. These drugs are extensively distributed around the body, as their high volume of distribution suggests.<span class="elsevierStyleSup">4,5</span> A new mTOR inhibitor, temsirolimus, has been recently introduced to the market, which is indicated in the treatment of advanced renal cell carcinoma.</p><p class="elsevierStylePara">It has been shown that mTOR inhibitors stimulate the production of some proinflammatory cytokines in monocytes and macrophages and promote the proliferation of memory T cells. This indicates that they possess certain proinflammatory effects that may be the cause of some of its adverse effects, such as pneumonitis, which is the inflammation of lung tissue.<span class="elsevierStyleSup">2</span> Table 1 shows the main studies on pneumonitis in patients treated with mTOR inhibitors.<span class="elsevierStyleSup">6-10</span></p><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><span class="elsevierStyleBold">INCIDENCE</span></p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">A lot of cases of pneumonitis due to mTOR inhibitors have been reported since they were first marketed, most associated with sirolimus treatment, although cases have also been described that involve everolimus and temsirolimus.<span class="elsevierStyleSup">3,11</span> The incidence of this adverse effect was estimated at 4-11%.<span class="elsevierStyleSup">6,8,9</span> However, the recent introduction of this group of drugs, specifically everolimus and temsirolimus as antineoplastic treatment, provides more case studies and suggests that the incidence is probably higher. Given that cancer patients periodically undergo computed axial tomography (CAT), we have been able to observe pulmonary abnormalities suggestive of pneumonitis in asymptomatic patients. The overall incidence of pneumonitis for mTOR inhibitors in this type of patient, symptomatic or not, seems to be over 20%.<span class="elsevierStyleSup">11,12</span> Mortality associated with pneumonitis due to sirolimus and everolimus is estimated at around 5%.<span class="elsevierStyleSup">2</span></p><p class="elsevierStylePara">The overwhelming majority of cases described occurred in kidney transplant patients, since it is in this type of transplantation that mTOR inhibitors were first administered. Nevertheless, cases of pneumonitis have also been reported in liver and heart transplant patients who presented similar characteristics.<span class="elsevierStyleSup">6,13,14</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold"> </span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">CLINICAL PRESENTATION</span></p><p class="elsevierStylePara">Pneumonitis caused by mTOR inhibitors has heterogeneous clinical manifestations and may begin with fever, fatigue, coughing and dyspnoea, nonspecific signs and symptoms, which does not facilitate diagnosis. It may appear at the beginning or after several years of treatment. In many cases, the chest X-ray did not show abnormalities, which were only observed in CAT scans. The most common findings in CAT scans were ground glass opacities, although additional peripheral infiltrates and patterns of bronchiolitis obliterans with organising pneumonia have also been observed. In some cases, signs of pulmonary fibrosis were also observed. Diagnosis is difficult and tends to be made by excluding other causes, such as infections, autoimmune diseases or toxicity due to other products.<span class="elsevierStyleSup">8,9,15,16</span> Clinical improvement upon discontinuation of the drug can confirm the diagnosis.<span class="elsevierStyleSup">8</span></p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">The pathophysiology of pneumonitis associated with mTOR inhibitors is not very well understood. Direct toxicity by drugs, immunological toxicity or a combination of both mechanisms has been proposed. In lung biopsies of affected patients, lymphocytic alveolitis has been observed, which favours the immune mediated toxicity hypothesis. However, the rapid response to drug discontinuation favours the direct toxicity hypothesis.<span class="elsevierStyleSup">2,15-17</span></p><p class="elsevierStylePara">Interestingly, it has been observed that patients who began post-transplant immunosuppression directly with mTOR inhibitors have a lower incidence of pneumonitis than those who started treatment with calcineurin inhibitors and subsequently changed to sirolimus or everolimus. The reason for this lower incidence is not known, but some authors suggest that it may be due to differences in renal function, since an increased incidence of pneumonitis in patients with abnormal renal function has been observed.<span class="elsevierStyleSup">9,18</span> Sometimes the reason for switching from calcineurin inhibitors to mTOR inhibitors is nephrotoxicity due to the former. Therefore, when switching to treatment with mTOR inhibitors, patients typically present worse renal function. This hypothesis is not very plausible since sirolimus and everolimus are metabolised by CYP3A4 and their renal excretion is negligible.<span class="elsevierStyleSup">4,5</span> However, other mechanisms by which renal function modifies tolerance to mTOR inhibitors cannot be discarded and it has been questioned whether a metabolite of renal elimination may be the cause of symptoms.</p><p class="elsevierStylePara">The potential relationship between the occurrence of pneumonitis and plasma drug concentrations has also been researched. In the sirolimus efficacy studies published to date, different target treatment concentrations have been used. While some authors have used predose concentrations of 5-10ng/ml, others opt for 10-15ng/ml or greater, depending on whether or not the treatments were combined with calcineurin inhibitors, as well as the post-transplant period.<span class="elsevierStyleSup">19</span> In the study by Weiner et al., although in most cases of pneumonitis, sirolimus concentrations were higher than both treatment margins (mean 16.7ng/ml), cases were also observed with concentrations below 10ng/ml. As such, plasma concentrations within therapeutic margins do not allow pneumonitis caused by mTOR inhibitors to be ruled out.<span class="elsevierStyleSup">9-15</span></p><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><span class="elsevierStyleBold">TREATMENT</span></p><p class="elsevierStylePara">The first measure to be taken in a potential case of pneumonitis due to mTOR inhibitors is the suspension of the drug involved in the process. This eliminates symptoms completely in many cases.<span class="elsevierStyleSup">8,9,20,21</span> The administration of high doses of corticosteroids is also advised, although no recommended dose has been established. It is necessary to bear in mind that most of these patients are already treated with low levels of corticosteroids to avoid graft rejection. However, in some case series, patients have evolved favourably without having received corticosteroids.<span class="elsevierStyleSup">9</span> Therefore, some authors suggest administering corticosteroids only in the most serious cases.<span class="elsevierStyleSup">8</span></p><p class="elsevierStylePara">Likewise, cases have been described in which the reduction of the mTOR inhibitor dose has been sufficient to eliminate pneumonitis.<span class="elsevierStyleSup">3</span> As an alternative to sirolimus discontinuation, switching to everolimus has also been proposed and has yielded good results in several cases. Everolimus is a more hydrophilic drug than sirolimus, making it easier to eliminate from the body and less likely to cause hypersensitive reactions.<span class="elsevierStyleSup">10,22</span> It seems that it presents a lower incidence of pneumonitis with respect to sirolimus<span class="elsevierStyleSup">3</span>, although some studies have not found any differences.<span class="elsevierStyleSup">1</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold"> </span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">CONCLUSION</span></p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">In solid organ transplant patients who are treated with mTOR inhibitors and have respiratory symptoms, after ruling out infection and other causes, we should suspect iatrogenic pneumonitis, in order that the appropriate treatment may begin as soon as possible: discontinuation or a change of immunosuppressive treatment and addition of corticosteroid treatment if necessary.</p><p class="elsevierStylePara">Given that pneumonitis due to mTOR inhibitors is more common in patients with renal failure and that cases have been described in which dose reduction eliminates clinical manifestations, we may be led to believe that this toxicity is dependent on concentrations of the drug in the body. However, patients with plasma concentrations within the treatment margin have presented this complication. Details of the pathophysiology of this disease are still unknown, but for drugs with a high volume of distribution, one possibility would be specific accumulation of the mTOR inhibitor or its metabolites in the lung parenchyma. This could explain the presence of serum concentrations within the therapeutic interval in patients with pneumonitis.</p><p class="elsevierStylePara">It seems that the mTOR inhibitors, although they have the same mechanism of action, seem to differ in terms of their adverse effects, with there being greater tolerance to everolimus. However, there is still a lack of data to confirm this.</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><span class="elsevierStyleBold">Conflicts of interest</span></p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">The authors declare that they have no conflicts of interest related to the contents of this article.</p><p class="elsevierStylePara"><a href="grande/11439_16025_46549_en_t111439.jpg" class="elsevierStyleCrossRefs"><img src="11439_16025_46549_en_t111439.jpg" alt="Main studies on pneumonitis in patients treated with mTOR inhibitors"></img></a></p><p class="elsevierStylePara">Table 1. Main studies on pneumonitis in patients treated with mTOR inhibitors</p>" "pdfFichero" => "P1-E550-S4070-A11439-EN.pdf" "tienePdf" => true "PalabrasClave" => array:2 [ "es" => array:6 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec435993" "palabras" => array:1 [ 0 => "Trasplante de órganos" ] ] 1 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec435995" "palabras" => array:1 [ 0 => "Everolimus" ] ] 2 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec435997" "palabras" => array:1 [ 0 => "Sirolimus" ] ] 3 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec435999" "palabras" => array:1 [ 0 => "Neumonitis" ] ] 4 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec436001" "palabras" => array:1 [ 0 => "Enfermedad pulmonar intersticial" ] ] 5 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec436003" "palabras" => array:1 [ 0 => "Inhibidores de mTOR" ] ] ] "en" => array:6 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec435994" "palabras" => array:1 [ 0 => "Organ transplantation" ] ] 1 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec435996" "palabras" => array:1 [ 0 => "Everolimus" ] ] 2 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec435998" "palabras" => array:1 [ 0 => "Sirolimus" ] ] 3 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec436000" "palabras" => array:1 [ 0 => "Pneumonitis" ] ] 4 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec436002" "palabras" => array:1 [ 0 => "Interstitial lung disease" ] ] 5 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec436004" "palabras" => array:1 [ 0 => "mTOR inhibitors" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "es" => array:1 [ "resumen" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">Introducción:</span> Los inhibidores de mTOR (del inglés <span class="elsevierStyleItalic">mammalian target of rapamycin</span>), sirolimus y everolimus, utilizados como tratamiento inmunosupresor en el trasplante de órganos sólidos, pueden producir efectos adversos graves, como la neumonitis intersticial. <span class="elsevierStyleBold">Incidencia y presentación clínica:</span> La incidencia de neumonitis intersticial se ha estimado entre el 4 % y el 11 %, aunque podría ser mayor. La mayoría de los casos publicados se ha producido en pacientes trasplantados renales en tratamiento con sirolimus. La presentación clínica es heterogénea, lo que dificulta el diagnóstico. Se acostumbra a observar alteraciones en la tomografía axial computarizada torácica, como opacidades en vidrio deslustrado. La fisiopatología es poco conocida. Sin embargo, se ha observado una mayor incidencia en pacientes con función renal alterada y en pacientes que habían recibido inhibidores de calcineurina previamente. La relación entre aparición de neumonitis y concentraciones plasmáticas de inhibidores de mTOR no está bien definida. <span class="elsevierStyleBold">Tratamiento:</span> La suspensión del fármaco y la administración de dosis altas de corticoides parecen ser efectivos. Otras alternativas terapéuticas, aunque más discutidas, son la reducción de la dosis del inhibidor de mTOR y el cambio de sirolimus a everolimus. <span class="elsevierStyleBold">Conclusión:</span> Se debe sospechar de neumonitis iatrogénica en pacientes trasplantados en tratamiento con inhibidores de mTOR y con síntomas respiratorios. Faltan datos concluyentes en cuanto a estrategias de tratamiento. Parece que everolimus podría ser mejor tolerado que sirolimus.</p>" ] "en" => array:1 [ "resumen" => "<p class="elsevierStylePara"><span class="elsevierStyleBold"><span class="elsevierStyleItalic">Introduction:</span></span><span class="elsevierStyleItalic"> mTOR (<span class="elsevierStyleItalic">mammalian target of rapamycin</span>) inhibitors sirolimus and everolimus, used as immunosuppressants in solid organ transplantation, may cause severe adverse effects, such as interstitial pneumonitis. <span class="elsevierStyleBold">Incidence and clinical presentation:</span> The estimated incidence of interstitial pneumonitis is 4-11% although it may be higher. Most reported cases have occurred in renal transplant recipients treated with sirolimus. Clinical presentation is heterogeneous, which makes diagnosis difficult. Abnormalities, such as ground glass opacities, are often found in computerised axial tomography scans of the chest. Physiopathology is not well-known. However, patients with abnormal renal function and those with previous calcineurin inhibitor treatment display a higher incidence. The relationship between pneumonitis and mTOR inhibitor plasma concentrations is not well defined. <span class="elsevierStyleBold">Treatment:</span> Drug discontinuation and administration of high doses of corticosteroids seems to be an effective treatment. mTOR inhibitor dose reduction and replacing sirolimus with everolimus are other alternatives, but they are still under discussion. <span class="elsevierStyleBold">Conclusion:</span> Iatrogenic pneumonitis must be suspected when a transplant recipient being treated with mTOR inhibitors presents respiratory symptoms. There is lack of conclusive data on treatment strategies. It appears that everolimus may be tolerated better than sirolimus.</span></p>" ] ] "multimedia" => array:1 [ 0 => array:8 [ "identificador" => "fig1" "etiqueta" => "Tab. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11439_16025_46549_en_t111439.jpg" "Alto" => 1065 "Ancho" => 2167 "Tamanyo" => 348743 ] ] "descripcion" => array:1 [ "en" => "Main studies on pneumonitis in patients treated with mTOR inhibitors" ] ] ] "bibliografia" => array:2 [ "titulo" => "Bibliography" "seccion" => array:1 [ 0 => array:1 [ "bibliografiaReferencia" => array:22 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Sánchez-Fructuoso AI, Ruiz JC, Pérez-Flores I, Gómez Alamillo C, Calvo Romero N, Arias M. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus. Transplant Proc 2010;42(8):3050-2. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20970607" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Cravedi P, Ruggenenti P, Remuzzi G. Sirolimus for calcineurin inhibitors in organ transplantation: contra. Kidney Int 2010;78(11):1068-74. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20703217" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Alexandru S, Ortiz A, Baldovi S, Milicua JM, Ruiz-Escribano E, Egido J, et al. Severe everolimus-associated pneumonitis in a renal transplant recipient. Nephrol Dial Transplant 2008;23(10):3353-5. [Article] <a href="http://www.ncbi.nlm.nih.gov/pubmed/18658177" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Product information: Rapamune, sirolimus. Wyeth-Ayerst Laboratories. Philadelphia, PA; 1999." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 4 => array:3 [ "identificador" => "bib5" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Product information: Zortress oral tablets, everolimus oral tablets. Novartis Pharma Stein AG. Stein, Switzerland; 2010." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 5 => array:3 [ "identificador" => "bib6" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Morcos A, Nair S, Keane MP, McElvaney NG, McCormick PA. Interstitial pneumonitis is a frequent complication in liver transplant recipients treated with sirolimus. Ir J Med Sci 2012;181(2):231-5. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22246568" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 6 => array:3 [ "identificador" => "bib7" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Bertolini L, Vaglio A, Bignardi L, Buzio C, De Filippo M, Palmisano A, et al. Subclinical interstitial lung abnormalities in stable renal allograft recipients in the era of modern immunosuppression. Transplant Proc 2011;43(7):2617-23. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21911134" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 7 => array:3 [ "identificador" => "bib8" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Errasti P, Izquierdo D, Martín P, Errasti M, Slon F, Romero A, et al. Pneumonitis associated with mammalian target of rapamycin inhibitors in renal transplant recipients: a single-center experience. Transplant Proc 2010;42(8):3053-4. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20970608" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 8 => array:3 [ "identificador" => "bib9" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Weiner SM, Sellin L, Vonend O, Schenker P, Buchner NJ, Flecken M, et al. Pneumonitis associated with sirolimus: clinical characteristics, risk factors and outcome-a single-centre experience and review of the literature. Nephrol Dial Transplant 2007;22(12):3631-7. [Article] <a href="http://www.ncbi.nlm.nih.gov/pubmed/17611248" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 9 => array:3 [ "identificador" => "bib10" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Rehm B, Keller F, Mayer J, Stracke S. Resolution of sirolimus-induced pneumonitis after conversion to everolimus. Transplant Proc 2006;38(3):711-3. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16647451" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 10 => array:3 [ "identificador" => "bib11" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Duran I, Siu LL, Oza AM, Chung TB, Sturgeon J, Townsley CA, et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 2006;42(12):1875-80. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16806903" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 11 => array:3 [ "identificador" => "bib12" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "White DA, Schwartz LH, Dimitrijevic S, Scala LD, Hayes W, Gross SH. Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus (RAD001). J Thorac Oncol 2009;4(11):1357-63. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19745764" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 12 => array:3 [ "identificador" => "bib13" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "David S, Kumpers P, Shin H, Haller H, Fliser D. Everolimus-associated interstitial pneumonitis in a patient with a heart transplant. Nephrol Dial Transplant 2007;22(11):3363-4. [Article] <a href="http://www.ncbi.nlm.nih.gov/pubmed/17724036" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 13 => array:3 [ "identificador" => "bib14" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Marín-Gómez LM, Cordero-Matía E, Gómez-Bravo MA, Bernal-Bellido C. Neumonitis asociada a everolimus en un receptor de trasplante hepático. Med Clin (Barc) 2010;135(9):431-2." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 14 => array:3 [ "identificador" => "bib15" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Martínez M, González Roncero FM, López M, Toro J, Valdivia MA, Pereira P, et al. Neumonitis intersticial asociada al uso de sirolimus en un trasplantado renal: un caso clínico. Nefrologia 2004;24 Suppl 3:7-10. [Article] <a href="http://www.ncbi.nlm.nih.gov/pubmed/15219060" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:1 [ "itemHostRev" => array:3 [ "pii" => "S1525861013001825" "estado" => "S300" "issn" => "15258610" ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib16" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Filippone EJ, Carson JM, Beckford RA, Jaffe BC, Newman E, Awsare BK, et al. Sirolimus-induced pneumonitis complicated by pentamidine-induced phospholipidosis in a renal transplant recipient: a case report. Transplant Proc 2011;43(7):2792-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21911165" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 16 => array:3 [ "identificador" => "bib17" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Singh U, Gupta A, Jasuja S. Sirolimus-induced pneumonitis. Indian J Nephrol 2009;19(2):80-1. [Article] <a href="http://www.ncbi.nlm.nih.gov/pubmed/20368931" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 17 => array:3 [ "identificador" => "bib18" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Sola E, López V, Gutiérrez C, Cabello M, Burgos D, Molina MG, et al. Late conversion to mammalian target of rapamycin inhibitor/proliferation signal inhibitors in kidney transplant patients: clinical experience in the last 5 years. Transplant Proc 2010;42(8):2859-60. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20970551" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 18 => array:3 [ "identificador" => "bib19" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Patel SJ, Elliott EN, Knight RJ, Gaber LW, Gaber AO. Considerations in sirolimus use in the early and late post-transplant periods. Expert Opin Drug Saf 2009;8(4):421-34. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19522662" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 19 => array:3 [ "identificador" => "bib20" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Davaus Gasparetto T, Marchiori E, Menezes P, Zanetti G. Pulmonary toxicity associated with sirolimus following kidney transplantation: computed tomography findings. Nefrologia 2010;30(2):259-60. [Article] <a href="http://www.ncbi.nlm.nih.gov/pubmed/20393625" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 20 => array:3 [ "identificador" => "bib21" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Losada González GP, Gómez Marqués G, Martínez Mateu JG, Munar Vila MA, Uriol Rivera M. Neumonitis intersticial por everolimus. Nefrologia 2010;30(4):479-80. [Article] <a href="http://www.ncbi.nlm.nih.gov/pubmed/20651895" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:1 [ "itemHostRev" => array:3 [ "pii" => "S1525861012004203" "estado" => "S300" "issn" => "15258610" ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib22" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Calle L, Tejada C, Lancho C, Mazuecos A. Neumonitis por sirolimus: resolución tras conversión a everolimus. Nefrologia 2009;29(5):490-1. [Article] <a href="http://www.ncbi.nlm.nih.gov/pubmed/19820768" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/20132514/0000003300000003/v0_201502091549/X2013251413003279/v0_201502091549/en/main.assets" "Apartado" => array:4 [ "identificador" => "35445" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Short Reviews" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/20132514/0000003300000003/v0_201502091549/X2013251413003279/v0_201502091549/en/P1-E550-S4070-A11439-EN.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251413003279?idApp=UINPBA000064" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 7 | 9 | 16 |
| 2024 October | 63 | 49 | 112 |
| 2024 September | 91 | 60 | 151 |
| 2024 August | 93 | 85 | 178 |
| 2024 July | 78 | 87 | 165 |
| 2024 June | 90 | 76 | 166 |
| 2024 May | 105 | 94 | 199 |
| 2024 April | 85 | 68 | 153 |
| 2024 March | 85 | 58 | 143 |
| 2024 February | 55 | 69 | 124 |
| 2024 January | 46 | 36 | 82 |
| 2023 December | 48 | 47 | 95 |
| 2023 November | 51 | 63 | 114 |
| 2023 October | 70 | 56 | 126 |
| 2023 September | 83 | 813 | 896 |
| 2023 August | 100 | 79 | 179 |
| 2023 July | 39 | 55 | 94 |
| 2023 June | 70 | 51 | 121 |
| 2023 May | 57 | 60 | 117 |
| 2023 April | 45 | 39 | 84 |
| 2023 March | 52 | 39 | 91 |
| 2023 February | 33 | 33 | 66 |
| 2023 January | 42 | 27 | 69 |
| 2022 December | 51 | 31 | 82 |
| 2022 November | 37 | 31 | 68 |
| 2022 October | 37 | 37 | 74 |
| 2022 September | 51 | 48 | 99 |
| 2022 August | 51 | 52 | 103 |
| 2022 July | 26 | 60 | 86 |
| 2022 June | 39 | 42 | 81 |
| 2022 May | 42 | 46 | 88 |
| 2022 April | 52 | 48 | 100 |
| 2022 March | 61 | 54 | 115 |
| 2022 February | 91 | 56 | 147 |
| 2022 January | 69 | 35 | 104 |
| 2021 December | 79 | 53 | 132 |
| 2021 November | 62 | 50 | 112 |
| 2021 October | 65 | 52 | 117 |
| 2021 September | 58 | 54 | 112 |
| 2021 August | 39 | 37 | 76 |
| 2021 July | 46 | 52 | 98 |
| 2021 June | 57 | 18 | 75 |
| 2021 May | 94 | 54 | 148 |
| 2021 April | 103 | 35 | 138 |
| 2021 March | 71 | 31 | 102 |
| 2021 February | 49 | 34 | 83 |
| 2021 January | 45 | 24 | 69 |
| 2020 December | 46 | 15 | 61 |
| 2020 November | 40 | 27 | 67 |
| 2020 October | 27 | 15 | 42 |
| 2020 September | 33 | 7 | 40 |
| 2020 August | 44 | 17 | 61 |
| 2020 July | 55 | 17 | 72 |
| 2020 June | 44 | 27 | 71 |
| 2020 May | 51 | 21 | 72 |
| 2020 April | 41 | 19 | 60 |
| 2020 March | 44 | 18 | 62 |
| 2020 February | 55 | 21 | 76 |
| 2020 January | 55 | 23 | 78 |
| 2019 December | 79 | 37 | 116 |
| 2019 November | 58 | 28 | 86 |
| 2019 October | 39 | 12 | 51 |
| 2019 September | 45 | 19 | 64 |
| 2019 August | 49 | 13 | 62 |
| 2019 July | 84 | 21 | 105 |
| 2019 June | 70 | 18 | 88 |
| 2019 May | 58 | 19 | 77 |
| 2019 April | 69 | 36 | 105 |
| 2019 March | 58 | 27 | 85 |
| 2019 February | 52 | 29 | 81 |
| 2019 January | 33 | 16 | 49 |
| 2018 December | 97 | 45 | 142 |
| 2018 November | 110 | 29 | 139 |
| 2018 October | 98 | 18 | 116 |
| 2018 September | 82 | 19 | 101 |
| 2018 August | 69 | 18 | 87 |
| 2018 July | 52 | 12 | 64 |
| 2018 June | 55 | 27 | 82 |
| 2018 May | 52 | 24 | 76 |
| 2018 April | 73 | 6 | 79 |
| 2018 March | 54 | 14 | 68 |
| 2018 February | 70 | 10 | 80 |
| 2018 January | 63 | 5 | 68 |
| 2017 December | 70 | 12 | 82 |
| 2017 November | 77 | 16 | 93 |
| 2017 October | 74 | 11 | 85 |
| 2017 September | 52 | 12 | 64 |
| 2017 August | 52 | 10 | 62 |
| 2017 July | 64 | 19 | 83 |
| 2017 June | 52 | 12 | 64 |
| 2017 May | 68 | 12 | 80 |
| 2017 April | 63 | 26 | 89 |
| 2017 March | 43 | 26 | 69 |
| 2017 February | 60 | 12 | 72 |
| 2017 January | 44 | 18 | 62 |
| 2016 December | 82 | 12 | 94 |
| 2016 November | 124 | 24 | 148 |
| 2016 October | 147 | 22 | 169 |
| 2016 September | 226 | 6 | 232 |
| 2016 August | 274 | 14 | 288 |
| 2016 July | 299 | 24 | 323 |
| 2016 June | 193 | 0 | 193 |
| 2016 May | 164 | 0 | 164 |
| 2016 April | 136 | 0 | 136 |
| 2016 March | 117 | 0 | 117 |
| 2016 February | 129 | 0 | 129 |
| 2016 January | 124 | 0 | 124 |
| 2015 December | 155 | 0 | 155 |
| 2015 November | 120 | 0 | 120 |
| 2015 October | 98 | 0 | 98 |
| 2015 September | 90 | 0 | 90 |
| 2015 August | 89 | 0 | 89 |
| 2015 July | 92 | 0 | 92 |
| 2015 June | 43 | 0 | 43 |
| 2015 May | 58 | 0 | 58 |
| 2015 April | 10 | 0 | 10 |
Show all
